“Based on the results from this trial, we entere

“Based on the results from this trial, we entered into a collaborative agreement with Merck Sharpe & Dohme B.V. (“Merck”) and the National Surgical Adjuvant Breast and Prostate Program (“NSABP”) to conduct a Phase II trial to evaluate the safety and efficacy of AE37 in combination with the anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with metastatic triple-negative breast cancer. The trial is currently enrolling patients, and the first treatment cohort has completed the initial assessment of the safety of AE37 in combination with Keytruda; enrollment is now expected to be completed by the end of 2020.”

(Covid probably completely thwarted any such timeline imho.)

https://sec.report/Document/0001607062-20-000057/